References
- SchoenfeldPEfficacy of current drug therapies in irritable bowel syndrome: What works and does not workGastroenterol Clin North Am200534231933515862938
- OldenKWDiagnosis of irritable bowel syndromeGastroenterology200212261701170412016433
- BarbaraGDe GiorgioRStanghelliniVCremonCSalvioliBCorinaldesiRNew pathophysiological mechanisms in irritable bowel syndromeAliment Pharmacol Ther200420Suppl 21915335408
- TalleyNJIrritable bowel syndromeIntern Med J2006361172472817040359
- MajewskiMMcCallumRWResults of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trialAdv Med Sci20075213914218217406
- PosserudIStotzerPOBjörnssonESAbrahamssonHSimrénMSmall intestinal bacterial overgrowth in patients with irritable bowel syndromeGut200756680280817148502
- Krogius-KurikkaLLyraAMalinenEMicrobial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferersBMC Gastroenterol200999520015409
- TanaCUmesakiYImaokaAHandaTKanazawaMFukudoSAltered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndromeNeurogastroenterol Motil201022551251919903265
- PimentelMChatterjeeSChowEJParkSKongYNeomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: Subanalysis of a double-blind randomized controlled studyDig Dis Sci20065181297130116832617
- PimentelMChowEJLinHCNormalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled studyAm J Gastroenterol200398241241912591062
- YangJLeeHRLowKChatterjeeSPimentelMRifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBSDig Dis Sci200853116917417520365
- PimentelMChowEJLinHCEradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndromeAm J Gastroenterol200095123503350611151884
- FrissoraCLCashBDThe role of antibiotics vs conventional pharmacotherapy in treating symptoms of irritable bowel syndromeAliment Pharmacol Ther200725111271128117509095
- BrandtLJCheyWDFoxx-OrensteinAEAn evidence-based position statement on the management of irritable bowel syndromeAm J Gastroenterol2009104Suppl 1S1S3519521341
- PimentelMParkSMirochaJKaneSVKongYThe effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndromeAnn Intern Med2006145855756317043337
- ShararaAIAounEAbdul-BakiHMounzerRSidaniSElHajjIA randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulenceAm J Gastroenterol2006101232633316454838
- PeraltaSCottoneCDoveriTAlmasioPLCraxiASmall intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with rifaximinWorld J Gastroenterol200915212628263119496193
- LowKHwangLHuaJZhuAMoralesWPimentelMA combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath testJ Clin Gastroenterol201044854755019996983
- PimentelMLemboACheyWDfor the TARGET Study GroupRifaximin therapy for patients with irritable bowel syndrome without constipationN Engl J Med20113641223221208106
- ScarpelliniEGabrielliMLauritanoCEHigh dosage rifaximin for the treatment of small intestinal bacterial overgrowthAliment Pharmacol Ther200725778178617373916